Imidazopyridine derivates were recently shown to be a novel class of selective and arginine-competitive inhibitors of inducible nitric-oxide synthase (iNOS), and 2-[2-(4-methoxypyridin-2-yl)-ethyl]-3H-imidazo [4,5-b]pyridine (BYK191023) was found to have very high selectivity in enzymatic and cellular models (Mol Pharmacol 69: 328 -337, 2006). Here, we show that BYK191023 irreversibly inactivates murine iNOS in an NADPH-and time-dependent manner, whereas it acts only as a reversible L-arginine-competitive inhibitor in the absence of NADPH or during anaerobic preincubation. Time-dependent irreversible inhibition by BYK191023 could also be demonstrated in intact cells using the RAW macrophage or iNOSoverexpressing human embryonic kidney 293 cell lines. The mechanism of BYK191023 inhibition in the presence of NADPH was studied using spectral, kinetic, chromatographic, and radioligand binding methods. BYK191023-bound iNOS was spectrally indistinguishable from L-arginine-bound iNOS, pointing to an interaction of BYK191023 with the catalytic center of the enzyme. [3 H]BYK191023 was recovered quantitatively from irreversibly inactivated iNOS, and no inhibitor metabolite was detected by high-performance liquid chromatography (HPLC). Size exclusion chromatography revealed only about 20% iNOS dissociation into monomers. Furthermore, HPLC and spectrophotometric analysis showed that the irreversible inhibition was associated with loss of heme from iNOS and a reduced ability to form the distinctive ferrous heme-CO complex (cytochrome P450). Thus, enzyme inactivation is mainly caused by heme loss, and it occurs in the inhibitorbound enzyme in the presence of electron flux from NADPH.NO is a highly diffusible biological messenger generated by nitric-oxide synthases (EC1.14.13.39; NOS), a family of enzymes that catalyze the NADPH-dependent conversion of L-arginine to L-citrulline and NO in a two-step process (Stuehr, 1999). In mammalian cells, three NOS isozymes [inducible (iNOS), neuronal (nNOS), and endothelial (eNOS)] evolved to have significant functional differences despite having considerable sequence homology (Michel and Feron, 1997). Each NOS isoform is a homodimeric hemoprotein made up of two separate domains connected by a calmodulin (CaM) binding polypeptide. The oxygenase domain contains sites for iron protoporphyrin IX (heme), 6R-tetrahydrobiopterin (H 4 B), and Larginine (Arg), whereas the reductase domain contains binding sites for FAD, FMN, and NADPH. During NO biosynthesis, the electron flux in the NOS enzymes goes via NADPH 3 FAD 3 FMN through the reductase domain of one monomer to the heme iron in the oxygenase domain of the second monomer (Alderton et al., 2001). Therefore, NOS is active only when the two monomers associate into a homodimeric protein. Under normal conditions, NO is released in small amounts (picomolar to nanomolar) by nNOS and eNOS, and it has a central role in the regulation of vasodilation and in neurotransmission. Pathological effects can occur either when NO production is lower o...